Cancer Therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 7, 2016
filing date -
Sep 28, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The prior art largely suggests that immune competence in a cancer patient would destroy an antigenic viral vector before it transfects host cells with a transgene-rendering therapy futile. We surprisingly found the opposite is true: cancer patients with competent immune systems obtain the most therapeutic benefit from antigenic viral vector, apparently because the antigenic viral vector, apart from transfecting cells with a transgene, induces a humoral immune response, which in turn attacks cells bearing cancer antigen. Our new therapy works particularly well in combination with cytotoxic chemotherapeutic drugs.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully